BASEL, Switzerland, Aug. 3 -- Sandoz, a company that say it focuses on generic pharmaceuticals and biosimilars, issued the following news release:

* * *

Sandoz takes further steps to resolve legacy US generic medicine litigation

Ad hoc announcement pursuant to art. 53 SIX Swiss Exchange Listing Rules

* When completed, settlement with 43 US states and territories would mean no remaining US federal or state governmental claims

* Sepa . . .

Click here for more information about our products